Tesaro (TSRO) Shares Double On Cancer Drug Success

You know champagne bottles are being popped open when your cancer drug treatment trial ends up being a success.

Shares of biopharmaceutical company Tesaro, exploded on Wednesday morning, after the company reported successful results of a cancer drug treatment trial.

The company announced that a trial of its drug niraparib (which is taken orally) “significantly prolonged” progression-free survival for patients with recurrent ovarian cancer compared to a control group. The trial included more than 500 patients with recurrent ovarian cancer.

The full results of the study will be released in October at the European Society for Medical Oncology congress.
Shares more than doubled in morning trading after the announcement.

Disclaimer: We have no position in TESARO Inc. (NASDAQ: TSRO) and have not been compensated for this article.

Sofia Vida

Sofia has been writing for major news outlets for over 15 years. In her spare time she enjoys hiking, walking her dogs, and going to concerts.

sophia-villa has 2020 posts and counting.See all posts by sophia-villa